FDA Okays First Biosimilar for Multiple Sclerosis
Sandoz's natalizumab-sztn injection (Tyruko) is on par with Biogen's Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.
Medscape Medical News
source https://www.medscape.com/viewarticle/995845?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/995845?src=rss
Comments
Post a Comment